CD270 (HVEM) Monoclonal Antibody (LH1), PE, eBioscience™, Invitrogen™

Description

• Description: The LH1 monoclonal antibody reacts with mouse Herpes Virus Entry Mediator (HVEM, TR2), a member of the TNF-receptor superfamily
• HVEM is found on most cell types, including T cells, B cells, monocytes, neutrophils and dendritic cells
• This receptor was identified as a cellular mediator of herpes simplex virus (HSV) entry
• Binding of HSV viral envelope glycoprotein D (gD) to this receptor protein has been shown to be part of the viral entry mechanism
• The cytoplasmic region of HVEM was found to bind to several TRAF family members, which may mediate the signal transduction pathways that activate the immune response
• HVEM has also been demonstrated to be a unique ligand for BTLA (B and T lymphocyte attenuator)
• The conservation of the BTLA-HVEM interaction between mouse and human suggests that this system is an important pathway regulating lymphocyte activation and/or homeostasis in the immune response
• The LH1 antibody has been reported as a blocking antibody, interfering with the HVEM-LIGHT interaction but not the HVEM-BTLA interaction
• Applications Reported: This LH1 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This LH1 antibody has been tested by flow cytometric analysis of mouse splenocytes
• This can be used at less than or equal to 0.125 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• TNFRSF14 is a member of the TNF-receptor superfamily
• TNFRSF14 was identified as a cellular mediator of herpes simplex virus (HSV) entry
• Binding of HSV viral envelope glycoprotein D (gD) to TNFRSF14 has been shown to be part of the viral entry mechanism
• The cytoplasmic region of TNFRSF14 was found to bind to several TRAF family members, which may mediate the signal transduction pathways that activate the immune response
• Activation of the signal transduction pathway involving TNFRSF14 in T cells stimulates T cell proliferation and cytokine production, leading to inflammation and enhanced CTL-mediated tumor immunity, suggesting that these proteins may be useful as potential targets for controlling cellular immune responses
• Multiple alternatively spliced transcript variants have been described, but the full-length nature of some of these TNFRSF14 variants have not been determined.